For now just a placeholder page. Visit repository at : https://github.com/Chess-engines-league/central


WITNESS LIST Transportation Committee March 6, 2001-2:00P HB 996 For: Lyons, Steve (Houston Police Department/City of Houston) HB 1378 For: Borel, Dennis (Coalition of Texans with Disabilities) Costello, Richard (Self) Stevenson, Michael W. (Self and Lufkin Mayor's Committee on People With Disabilities) Zoern, Stacy (Self and Coalition of Texans with Disabilities) Registering, but not testifying: For: Gadbois, Glenn (Texas Citizen Fund) On: Hunt, Darrel (Texas Department of Transportation) HB 1535 On: Hunt, Darrel (Texas Department of Transportation) Registering, but not testifying: For: Cernosek, Larry (Texas Towing and Storage Association) Huffman, Jeff (Texas Credit Union League) Smith, Steve (Self) On: Berasley, Ann (Comptroller of Public Accounts) HB 1594 For: Rome, Harding (Union Pacific Railroad Company) Registering, but not testifying: For: Arterburn, David (United Transportation Union) Barton, Bill (Texas Railroad Association) English, Jr., C.M. (United Transportaiton Union) Hinojosa, Walter (Texas AFL-CIO) Holmes, Raymond (Brotherhood of Locomotive Engineers) Kearns, Dennis (Burlington Northern Santa Fe Railway) Littles, Paula (Texas AFL-CIO) Olson, Ron M. (Union Pacific Railroad) Rodriguez, Robert Patrick (Rodriguez, Colvin & Chaney, L.L.P., and Union Pacific Railroad) Watkins, Joe Bill (Kasas City Southern Railraod) HB 1661 Registering, but not testifying: For: McCarley, James (Dallas Regional Mobility Coalition) McCarley, James (Texas Credit Union Coalition) On: Bawson, Carol (Texas Department of Transportation) Russell, Phillip (Texas Department of Transportation) HB 1679 Registering, but not testifying: For: Cernosek, Larry (Texas Towing & Storage Association) Smith, Stephen H. (Self and Texas Towing and Storage Association) On: Smith, Lawrance (Texas Department of Transportation) HB 1697 Registering, but not testifying: On: Campbell, John (Texas Department of Transportation) HB 1718 For: Jackson, Lee (Dallas County Commissioners Court) Registering, but not testifying: For: Hiebert, Jerry (North Texas Tollway Authority) McCarley, James (Dallas Regional Mobility Coalition)


The Players’ Tribune, founded by Derek Jeter, has been acquired by Minute Media, which owns Mental Floss and other big sites.
The former New York Yankee announced the “new partnership” in a personal column on TPT on Thursday.
Jeter began his column by referencing the community of athletes who shared their voices in personal articles on the site since it was launched in 2014.
Also Read:
“And it’s with this global athlete community in mind that, over the past year, we’ve been looking for the right partner to help us expand internationally. Our vision has always been to give athletes the tools they need to tell their story in their own words, and bring fans closer to the games they love,” he said. “After a lot of thought and discussion, we’ve found the right partner to allow us to do that in more countries around the world.”
Also Read:
In a tweet, Minute Media also heralded the news, writing, “We are excited to announce @PlayersTribune as the newest addition to our brand portfolio! This strategic acquisition marks an exciting new chapter for both Minute Media and The Players’ Tribune!”
When he retired from baseball in 2014, Jeter launched the TPT which, at the time, TheWrap reported was “a new platform for sports stars to connect with fans directly, instead of talking through sports journalists or social media.”
Founded in 2011, Minute Media has grown to three different platforms and along with acquiring media assets including as Mental Floss,The Big Lead and now TPT.
Rob Gronkowski, Snoop Dogg, Nikki Bella Fuel ESPYS Week Parties (Photos) The biggest day in sports now lasts a whole week, with ESPN, Nickelodeon, Players’ Tribune and Sports Spectacular joining the action View In Gallery


Detailed course offerings (Time Schedule) are available for
PCEUT 499 Undergraduate Research (1-6, max. 12)
Research problems in drug disposition, drug targeting, and drug development. Prerequisite: cumulative GPA of 2.50 and permission of instructor.
View course details in MyPlan: PCEUT 499
PCEUT 501 Advanced Pharmacokinetics I (5) Lin, Prasad, Unadkat
Drug absorption, distribution, excretion, metabolism, and pharmacological effects in mammalian systems. Compartmental and physiologically-based pharmacokinetic models as well as non-compartmental approaches examined. Drug disposition studied in a physiologically realistic context taking nonlinear events into account. Aimed at development of innovative methods for data analysis (including population pharmacokinetic and pharmacodynamic models) and evaluation in biological systems. Prerequisite: PCEUT 506 or permission of instructor. Offered: even years.
View course details in MyPlan: PCEUT 501
PCEUT 502 Pharmacokinetics of Drug Metabolism (4) Isoherranen, Thummel
Advanced study of drug metabolism pharmacokinetics. Topics emphasize linear and nonlinear metabolic clearance kinetics, drug-drug interaction mechanisms and kinetics, metabolite kinetics, in vitro-in vivo predictions, pharmacogenetics and other sources of inter-individual variability. Prerequisite: PCEUT 506 or permission of instructor. Offered: even years.
View course details in MyPlan: PCEUT 502
PCEUT 503 Drug Transport and Delivery (5) Ho, Hu, Mao, Shen, Unadkat, Wang
Provides advance knowledge of the physico-chemical and biological concepts underlying in vivo transport and delivery of drugs. Prerequisite: PCEUT 506.
View course details in MyPlan: PCEUT 503
PCEUT 506 Pharmacokinetic Principles (6) Lin
Covers the fundamentals of pharmacokinetics. Includes lectures and laboratory exercises on the key concepts in pharmacokinetics, including compartmental kinetics, clearance, protein binding, bioavailability, pharmacodynamics, clinical pharmacokinentics, and Michaelis-Menten kinetics.
View course details in MyPlan: PCEUT 506
PCEUT 510 Drug Interactions (3) Collins, Horn, Lin, Shen
Covers common pharmacokinetic mechanisms underlying clinically important interactions between drugs, and patient- and drug-related factors that predispose a patient to adverse drug effects. Includes case-based discussion of approaches to identification, clinical evaluation, and clinical management of drug-drug interaction risk. Prerequisite: PHARM 558; PHARM 559; PHARM 560; PHARM 561; PHARM 563; PHARM 564, and PHARM 565.
View course details in MyPlan: PCEUT 510
PCEUT 513 Basic Concepts in Pharmacogenetics and Toxicogenomics (3)
Addresses current technologies for DNA sequencing, genotyping, RNA and epigenetic analysis and basic concepts of pharmacogenetics and toxicogenomics. Emphasis placed on applications of genomic technologies to the understanding of "gene-environment interactions" that cause variability in drug treatment responses, as well as diseases of public health importance, including cancer, chronic neurological diseases, and adverse drug reactions. Offered: jointly with ENV H 513/PHG 513; W.
View course details in MyPlan: PCEUT 513
PCEUT 520 Seminar (1, max. 30) A. NATH
Graduate students attend seminars and make one formal presentation per year while in residence; maximum of three presentations. Credit/no-credit only. Offered: jointly with MEDCH 520.
View course details in MyPlan: PCEUT 520
PCEUT 531 P-Pharmaceutical Formulation: Principles and Dosage Forms (4) Lee, Mao, Shen
Physiochemical principles involved in formulating stable dosage forms suitable for human administration. Hands-on laboratory experience with formulating extemporaneous preparations routinely encountered in community and hospital pharmacies. Routes of drug administration.
View course details in MyPlan: PCEUT 531
PCEUT 532 P-Clinical Pharmacokinetics (4) Anderson, Isoherranen, Unadkat, Wang
Covers basic principles of pharmacokinetics and their application to the clinical setting, including: single-dose intravenous and oral kinetics, multiple dosing, nonlinear pharmacokinetics, metabolite kinetics, pharmacogenetics, and the role of disease in drug clearance and dose requirements, and kinetics of drug-drug interactions. Prerequisite: PCEUT 531.
View course details in MyPlan: PCEUT 532
PCEUT 533 P-Biopharmaceutics, Drug Delivery and Therapeutic Resonse (3) R. HO, S. HU, K. THUMMEL
Provides basic principles of biopharmaceutics, drug delivery and therapeutic response, and their application to traditional and biotherapeutics, including oral and non-oral routes of drug administration. Discussion include fundamental principles related to assessment of bioavailability, bioequivalence, and genetic basis for drugs. Offered: Sp.
View course details in MyPlan: PCEUT 533
PCEUT 570 Advanced Research Topics (1, max. 15)
Combines a discussion of the practical aspects and experimental techniques used to address the questions relating to drug disposition with comprehensive theoretical treatment of pharmacokinetic principles. Prerequisite: permission of the instructor. Credit/no-credit only.
View course details in MyPlan: PCEUT 570
PCEUT 583 Topics in Pharmaceutics (1, max. 30) N. KLATT, K. THUMMEL
Discussion of pertinent articles from current literature and recent laboratory results. Credit/no-credit only.
View course details in MyPlan: PCEUT 583
PCEUT 584 Pharmacokinetic Discussion Group (2) Lin
Student initiated discussions of pharmaceutics concepts in relation to current literature. Preparatory to departmental cumulative examinations. Credit/no-credit only.
View course details in MyPlan: PCEUT 584
PCEUT 586 Biotechnology and Biopharmaceutics (2-3) Ho, Hu, Kelly, Thummel
Current topics in pharmaceuticals and biotechnology focusing on transforming small molecules, proteins, and genes into therapeutic products. Includes new drug therapies, drug design, pharmacogenomics, molecular modeling, high throughput screen, production and stability considerations, and delivery systems of protein and gene therapeutics in relation to pharmacokinetic and therapeutic responses.
View course details in MyPlan: PCEUT 586
PCEUT 587 Introduction to Biopharmaceutical Product Development (3)
Provides a framework of the drug development process and its regulation. Prerequisite: ENV H 405 or ENV H 514, ENV H 515, and ENV H 516, or PCEUT 501, PCEUT 502, and PCEUT 503; or equivalent, or instructor permission. Offered: jointly with ENV H 587; A, even years.
View course details in MyPlan: PCEUT 587
PCEUT 598 Independent Research (*, max. 24)
Basic and clinical research problems in drug disposition and effect. Prerequisite: minimum grade of 2.50 GPA and permission of instructor.
View course details in MyPlan: PCEUT 598
PCEUT 599 Cumulative Exams for Pharmaceutics (1-, max. 3) Isoherranen
Quarterly cumulative examinations for graduate students.
View course details in MyPlan: PCEUT 599
PCEUT 600 Independent Study or Research (*-)
Credit/no-credit only.
View course details in MyPlan: PCEUT 600
PCEUT 700 Master's Thesis (*-)
Credit/no-credit only.
View course details in MyPlan: PCEUT 700
PCEUT 800 Doctoral Dissertation (*-)
Credit/no-credit only.
View course details in MyPlan: PCEUT 800


Search websites, locations, and people
A physics (opens in new window) experiment using light from
ancient quasars adds more support for
quantum entanglement, the seemingly
far-out idea that two particles, no matter how distant from each other, can be inextricably linked.
Want more?
Explore past Spotlights, or subscribe to receive daily or weeklydoses of MIT in your inbox.


Get citation for datasets used
gbif_citation(x)
| x | (character) Result of call to |
|---|
list with S3 class assigned, used by a print method to pretty print citation information. Though you can unclass the output or just index to the named items as needed.
Returns a set of citations, one for each dataset. We pull out unique dataset keys and get citations, so the length of citations may not be equal to the number of records you pass in.
Currently, this function gives back citations at the dataset level, not at the individual occurrence level. If occurrence keys are passed in, then we track down the dataset the key is from, and get the citation for the dataset.
# NOT RUN { res1 <- occ_search(taxonKey=9206251, limit=2) (xx <- gbif_citation(res1)) res2 <- occ_search(datasetKey='7b5d6a48-f762-11e1-a439-00145eb45e9a', return='data', limit=20) (xx <- gbif_citation(res2)) # if no datasetKey field included, we attempt to identify the dataset ## key field included - still works res3 <- occ_search(taxonKey=9206251, fields=c('name','basisOfRecord','key'), limit=20) (xx <- gbif_citation(res3)) ## key field not included - errors # res3 <- occ_search(taxonKey=9206251, fields=c('name','basisOfRecord',' # protocol'), limit=20) # (xx <- gbif_citation(res3)) # character class inputs ## pass in a dataset key gbif_citation(x='0ec3229f-2b53-484e-817a-de8ceb1fce2b') ## pass in an occurrence key gbif_citation(x='1425976049') # pass in an occurrence key as a numeric (won't work for a dataset key) gbif_citation(x=1425976049) # Downloads ## occ_download_get() # d1 <- occ_download("country = BG", "year <= 2011") # key <- "0000122-171020152545675" # occ_download_meta(key) # d1 <- occ_download_get(key, overwrite = TRUE) # gbif_citation(d1) ## occ_download_meta() # key <- "0000122-171020152545675" # res <- occ_download_meta(key) # gbif_citation(res) # }


NCATS TRANSLATOR KNOWLEDGE.BIO
LAUNCH
WHAT IS IT?
The NCATS Translator Initiative Knowledge.Bio web client application is an open-source project that allows its users to discover and
document biomedical connections across multiple distributed "Knowledge Beacons", that is, online biomedical databases that implement the
NCATS Knowledge Beacon Web Application Programming Interface.
1
enter a keyword
2
refine your search
3
add to map
4
arrange your concept map
5
find related evidence (e.g. journal citations)
6
search public library of concept maps
USE CASE
Here is an example of what you can discover.
Given a patient with a mutation in the Sepiaterin Reductase (SPR) gene and a collection of Movement Disorders and significantly disrupted sleep, what treament might you offer them?
The answer is contained in the
Knowledge.bio graph depicted here (and in Figure 1 of a ground breaking paper in
Science Translational Medicine).


Toggle navigation
Collections
Expenses
Balance Sheet
Liquidation Report
Logout
Another action
Something else here
Separated link
Accounts
Users
Roles
Locales
Locales
Finance
Expense Types
Collection Types
The Date
Audit Day (Y/N)
System Day Number
Add Entry


<< Previous Session
|
Next Session >>
Assessment - Lecture Quiz
Lecture 15: Forward and Futures Markets
1
.
Together with a Russian co-author, Professor Shiller conducted a survey in the U.S. and in Russia in 1991. The survey asked: ''Grain traders in capitalist countries sometimes hold grain without selling it, putting it in temporary storage in anticipation of higher prices later. Do you think this speculation will cause more frequent shortages of flour, bread and other grain products? Or will it cause such shortages to become rarer?'' What was the result of this survey?
Points = 2.0
Only very few people in Russia as well as the U.S. thought that shortages would become more frequent.
A big fraction in Russia thought that shortages would become more frequent, whereas people in the U.S. appreciated the advantages of forwards and futures market in that shortages become rarer.
A big fraction in the U.S. thought that shortages would become more frequent, whereas people in Russia appreciated the advantages of forwards and futures market in that shortages become rarer.
A significant fraction of people in both countries expected shortages to become more frequent. Comparing the two countries, less people in Russia adhered to this view.
2
.
What is the name of the price pattern, if futures prices are increasing in time to maturity?
Points = 2.0
Backwardation.
Fair value.
Contango.
Futures are only traded for specific maturity date, so that it is impossible to draw a curve of futures prices against time to maturity.
3
.
Consider the fair value equation for a commodities future, relating the futures price to the risk-free interest rate, a positive storage cost, and the spot price. This fair value equation implies that futures prices should be increasing in the time to maturity. Does this necessarily imply that any backwardated price pattern represents an exploitable profit opportunity?
Points = 2.0
Actually, the described fair value equation implies a backwardated price pattern, not a contango price pattern.
No, the underlying commodity might involve a convenience yield, which may cause a backwardated price pattern.
Yes, backwardated prices always represent an exploitable profit opportunity.
The stated fair value equation does not apply to commodity futures.
4
.
Which of the following statements is true about oil markets from 1870 until today?
(More than one answer may apply.)
Points = 2.0
From the 1940s until the 1960s, the Texas Railroad Commission worked to stabilize oil prices.
The first oil crisis in 1973-1974 was created by a blockade against oil in oil-producing countries outside the U.S.
The second oil crisis in 1979-1980 was associated with the Iranian revolution that led to the fall of the Shah of Iran.
The spikes in oil prices mentioned in class have, at the time of their occurrence, produced booms in the U.S. economy.
5
.
Consider futures contracts with the S&P 500 index as the underlying. How are these contracts settled at the maturity date?
Points = 2.0
The short position in the futures contract has to make sure to deliver all 500 stocks that are represented in the S&P 500 index in the appropriate numbers to exactly replicate the index composition.
The short position in the futures contract has to deliver shares in an index fund that tracks the S&P 500.
The long position in the futures contract has to deliver shares in an index fund that tracks the S&P 500.
S&P 500 futures are cash settled, that is only money changes hands according to the difference between the price specified in the futures contract and the current value of the S&P 500.
Status
Submit
Close